Profound Medical (PROF) Q1 2026 earnings review
Triple-Digit Growth and Historic Payer Win De-Risk the Path to Profitability
Profound Medical delivered 104% YoY revenue growth in Q1, reaching $5.3M. While total revenue dipped sequentially from Q4's peak, the underlying fundamentals are strengthening: recurring revenue grew sequentially, and operating expenses dropped 9% YoY as the CAPTAIN trial completed enrollment, shrinking the net loss by 34% to $7.1M. The most significant development is Humana becoming the first national commercial payer to cover the TULSA Procedure. Management guided FY26 revenue to ~$25M (+56% YoY), setting a realistic bar that accounts for the inherent lumpiness of capital equipment sales.
🐂 Bull Case
Humana is the first national payer to cover the TULSA Procedure, adding 6.9M covered lives. This serves as a massive validation milestone and opens the floodgates for Medicare Advantage patients, significantly de-risking the commercialization pathway.
The newly disclosed 'TULSA INDEX20' (20 mature sites) shows average procedures per site climbed from 7.1 in 25Q1 to 11.3 in 26Q1—a 59% YoY increase. Physicians are shifting from trial to routine use.
🐻 Bear Case
Capital equipment comprised 54% of Q1 revenue ($2.9M). Because capital sales are lumpy, overall revenue predictability remains low, evidenced by the sequential decline in total revenue from $6.0M in 25Q4 to $5.3M in 26Q1.
Despite management hyping the TULSA-AI Volume Reduction module for BPH as a catalyst that would 'triple the TAM' in 2025, Q1 procedures strictly for BPH were only 4% (plus 16% Hybrid). This is effectively flat sequentially versus 25Q4 (3% BPH, 17% Hybrid).
⚖️ Verdict: 🟢
Bullish. The Humana coverage decision is a watershed moment that structurally changes the company's TAM access. Combined with falling operating expenses, steady same-store utilization growth, and validation from the CAPTAIN trial, the investment narrative is shifting from clinical risk to commercial execution.
Key Themes
Humana Payer Coverage Changes the Game
Humana becoming the first national commercial payer to cover the TULSA Procedure is a landmark victory. Adding approximately 8.5 million total covered lives (6.9 million from Humana alone) directly addresses the company's biggest historical bottleneck: private payer reluctance. Because Humana is a dominant force in Medicare Advantage, this provides immediate financial relief to hospital systems adopting the technology and sets a precedent for other major commercial insurers.
Same-Store Utilization is Accelerating
Management introduced the 'TULSA INDEX20' to track 20 established sites (active >12 months). The trajectory is undeniably positive: average quarterly procedures per site grew consistently from 7.1 (25Q1) to 11.3 (26Q1). Annualized, these mature sites are now performing over 45 procedures per year, approaching management's long-term profitability target of 50 procedures per site.
Capital Sales Dominate Revenue Mix
While total revenue grew 104% YoY, the composition remains heavily skewed toward one-time capital equipment sales ($2.86M) rather than high-margin recurring consumables ($2.47M). Recurring revenue grew 37% YoY, significantly trailing the 249% surge in capital sales. Until recurring revenue becomes the dominant line item, top-line results will remain vulnerable to unpredictable hospital purchasing cycles.
CAPTAIN Trial Meets Primary Endpoint
The Level 1 CAPTAIN trial formally announced superiority on its prespecified, primary safety endpoint compared to robotic radical prostatectomy for intermediate-risk prostate cancer. This provides the ultimate clinical ammunition the sales team needs to mandate TULSA inclusion in professional society guidelines (e.g., AUA).
BPH Application Fails to Show Expected Breakout
In 2025, management aggressively touted the new TULSA-AI Volume Reduction software, claiming it would make TULSA competitive in the massive Benign Prostatic Hyperplasia (BPH) market and account for 'double-digit percentages' of volume. Data contradicts this breakout: isolated BPH procedures were just 4% of Q1 volume (up a negligible 100 bps sequentially from Q4), and Hybrid (Cancer + BPH) was 16% (down 100 bps sequentially). Prostate cancer remains the overwhelming driver (71%).
Operating Expenses Have Peaked
For the first time during its commercial ramp, operating expenses fell YoY, dropping 9% to $11.8M. This decline was driven by lower clinical trial costs (due to CAPTAIN trial enrollment completion), reduced travel, and lower insurance premiums. With $50.3M in cash remaining and cash burn shrinking, the threat of near-term dilutive capital raises has materially decreased.
Other KPIs
Accelerating YoY (+37% from $1.8M in 25Q1) and Stable sequentially (+7% from $2.3M in 25Q4). This metric strips out the noise of capital equipment placements and proves that installed systems are actively treating patients and consuming one-time use devices.
Stable. Gross margin ticked up slightly from 71% in 25Q1. The company noted that the improvement is tied to product mix, specifically a higher concentration of capital equipment sales, which currently carry strong margins. Sustaining >70% margin is critical to the profitability model.
Stable. Reached 80 installed systems by the end of Q1, up slightly from 78 at the end of 25Q4. Crucially, the company has an additional 6 systems shipped but not yet installed, indicating a healthy backlog of site activations heading into Q2.
Guidance
Decelerating YoY growth relative to Q1, but represents a stable, strong baseline. The implied 56% full-year growth is lower than Q1's 104% print. Management explicitly noted they are 'setting what we believe is a reasonable bar' because predicting short-term hospital capital equipment cycles remains difficult for analysts.
Stable. The company expects to maintain its current profitability profile across the full year, signaling that they do not intend to heavily discount capital placements or consumables to chase the $25M revenue target.
Key Questions
Humana Coverage Implementation
With Humana now covering the TULSA Procedure, what is the expected lag time between this policy decision and an observable acceleration in procedure volumes? How are you actively marketing this coverage to your installed base?
BPH Adoption Hurdles
Procedures strictly for BPH remained flat at 4% of total volume this quarter. Why isn't the TULSA-AI Volume Reduction module driving faster standalone BPH adoption, and are there specific workflow or economic barriers limiting its use compared to other BPH modalities?
Capital Pipeline Conversion
You shipped 6 uninstalled systems in Q1. Is the bottleneck for installation primarily on the hospital side (e.g., room preparation, staffing) or internal logistics, and what is the typical timeframe from shipment to first commercial procedure?